Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Checked against the public recordLast updated Oct 2, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- NGM Biopharmaceuticals, Inc
- Interventions being studied
- Drug: NGM707; Drug: NGM707 plus pembrolizumab (KEYTRUDA®); Drug: NGM707 plus pembrolizumab (KEYTRUDA®); Drug: NGM707 plus pembrolizumab (KEYTRUDA®); Drug: NGM707 plus pembrolizumab (KEYTRUDA®); Drug: NGM707; Drug: NGM707; Drug: NGM707
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy. * Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for their tumor type, and for which the patient was eligible and willing to receive, or refused SOC treatments that are perceived to have marginal clinical benefit. * Adequate bone marrow, kidney and liver function. * Performance status of 0 or 1. * Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement. Exclusion Criteria: * Prior treatment targeting ILT2 and/or ILT4 or targeting HLA-G.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- NGM Clinical Study SiteLos Angeles, California
- NGM Clinical Study SiteNewport Beach, California
- NGM Clinical Study SiteSanta Monica, California
- NGM Clinical Study SiteSanta Rosa, California
- NGM Clinical Study SiteLone Tree, Colorado
- NGM Clinical Study SiteWashington D.C., District of Columbia
- NGM Clinical Study SiteSarasota, Florida
- NGM Clinical Study SiteBaltimore, Maryland
- NGM Clinical Study SiteBoston, Massachusetts
- NGM Clinical Study SiteGrand Rapids, Michigan
- NGM Clinical Study SiteOmaha, Nebraska
- NGM Clinical Study SiteAlbany, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 2, 2024. Always confirm current availability with the study team.